Pharmaceutical drug prices and trends for CYTOMEL

Subscribe to access the full database, or Get Started Free
Drug Name	NDC	Price/Unit ($)	Unit	Date
CYTOMEL 25 MCG TABLET	60793-0116-01	0.50989	EACH	2025-11-19
CYTOMEL 5 MCG TABLET	60793-0115-01	0.36793	EACH	2025-11-19
CYTOMEL 25 MCG TABLET	60793-0116-01	0.50898	EACH	2025-10-22
CYTOMEL 5 MCG TABLET	60793-0115-01	0.36829	EACH	2025-10-22
CYTOMEL 5 MCG TABLET	60793-0115-01	0.36864	EACH	2025-09-17
CYTOMEL 25 MCG TABLET	60793-0116-01	0.50977	EACH	2025-09-17
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: July 27, 2025

Introduction

CYTOMEL, marketed primarily under the generic name Liothyronine Sodium, is a synthetic form of triiodothyronine (T3), the active thyroid hormone that regulates metabolic processes. It is prescribed chiefly for hypothyroidism and certain thyroid cancers, often as an adjunct to levothyroxine. Given its critical role in thyroid management and the evolving landscape of thyroid disorder treatments, understanding the market dynamics, competitive environment, and future price trajectories for CYTOMEL is essential for stakeholders.

This analysis explores current market fundamentals, competitive forces, regulatory influences, supply-demand factors, and potential price trends, equipping pharmaceutical companies, investors, and healthcare policymakers with actionable insights.

Market Overview

Current Market Size and Demand Drivers

Despite being an established generic drug, CYTOMEL's demand remains substantial. The prevalence of hypothyroidism affects approximately 5% of the general population, with higher incidence noted in women over 60 years (up to 9%) ([1]). While levothyroxine (T4) remains the first-line therapy, Liothyronine Na+ (CYTOMEL) is often used in specific cases such as myxedema coma or when patients are refractory to T4 therapy.

According to IQVIA data, global sales of Liothyronine products, including CYTOMEL, approximate USD 200 million annually, with the United States accounting for a significant proportion due to high disease prevalence and extensive healthcare infrastructure. However, this figure fluctuates based on regulatory changes, drug shortages, and prescribing trends.

Regulatory Environment

The U.S. Food and Drug Administration (FDA) has historically approved generic Liothyronine sodium formulations. Notably, in 2018, the FDA approved a new generic version, intending to enhance supply security and pricing competition. However, in late 2018, shortages emerged, primarily due to manufacturing challenges, leading to increased prices and off-label use suppression ([2]).

In Europe, regulatory agencies like the EMA maintain stringent standards for thyroid drugs, impacting market access and pricing strategies.

Supply Chain and Manufacturing Factors

Manufacturing complexities and low profit margins characterize Liothyronine sodium's production, leading to limited supplier numbers and occasional shortages. The drug's chemical synthesis involves stringent quality controls due to its narrow therapeutic index, adding to production costs. As a result, supply disruptions directly influence market prices and accessibility.

Competitive Landscape

Market Players

Major pharmaceutical companies—including Mylan, Lupin, and Teva—manufacture generic Liothyronine sodium. Recently, some manufacturers have exited the market citing low profitability, further constraining supply.

Innovative approaches, such as compounded thyroid medications or controlled-release formulations, have emerged as alternatives but face regulatory hurdles and variable clinical efficacy.

Market Entry Barriers

Barriers to new entrants include high manufacturing quality standards, limited market size, regulatory approval timelines, and existing supply constraints. These factors contribute to a concentrated supplier base, traditionally leading to price rigidity; however, shortages have led to price surges.

Substitutes and Off-Label Alternatives

While levothyroxine remains the mainstay, Liothyronine is sometimes preferred in complex cases like central hypothyroidism or certain thyroid cancers. Emerging therapies, such as instant-release T3 formulations and combination T4/T3 therapies, may influence demand dynamics in the future ([3]).

Price Dynamics and Future Projections

Historical Price Trends

CYTOMEL's average wholesale price (AWP) has experienced significant volatility over the past five years. During shortages, prices spiked by over 300%, with some sources reporting retail prices exceeding $100 per tablet, versus pre-shortage prices around $10–$20.

Post-shortage stabilization has been slow, with prices remaining elevated compared to historical levels, primarily attributed to limited manufacturing capacity and regulatory hurdles.

Factors Influencing Future Pricing

Supply Chain Stability: Manufacturing scalability and regulatory approvals for new generic entrants could stabilize supply, exerting downward pressure on prices. Conversely, persistent shortages or regulatory restrictions could sustain elevated prices.
Regulatory Changes: The FDA's efforts to incentivize new entrants and streamline manufacturing approvals could improve supply, potentially lowering prices. Conversely, increased quality standards could elevate production costs for existing or new suppliers.
Market Demand Fluctuations: A shift towards favoring more convenient or alternative therapies (e.g., combined T4/T3 regimens) could diminish demand for CYTOMEL, exerting downward pressure on prices.
Healthcare Policy and Reimbursement: Changes in insurance coverage, reimbursement policies, or formulary preferences could influence prescribing patterns and prices.

Price Projection Outlook

Based on current trends and market forces, the following projections are reasonable:

Short-term (1-2 years): Prices are likely to remain volatile, with potential decreases if supply disruptions are addressed through new entrants or manufacturing innovations. However, existing shortages may sustain higher prices temporarily.
Medium-term (3-5 years): If regulatory incentives translate into increased manufacturing capacity, prices may decrease by 10–30%. Conversely, persistent supply issues or increased regulatory hurdles could sustain elevated prices or cause further fluctuations.
Long-term (>5 years): Market normalization is possible with technological advances or shifts in prescribing practices. Otherwise, prices may remain relatively high in a constrained supply environment.

Regulatory and Market Strategy Implications

Stakeholders should monitor FDA and EMA policies actively, as regulatory changes can significantly impact supply and pricing. Strategic partnerships with manufacturers, investment in supply chain resilience, and flexibility in formulation development could mitigate risks.

For investors, fluctuating prices driven by supply constraints and regulatory shifts present opportunities for strategic entry during shortages or exit during oversupply scenarios. Healthcare payers and providers need to consider formulary management and alternative therapies as part of cost-containment measures.

Key Takeaways

CYTOMEL (Liothyronine Sodium) remains an important but niche component of thyroid disorder treatment, with demand driven by complex cases and specific clinical indications.
Market supply constraints, primarily due to manufacturing complexities and limited competition, have historically driven volatile prices, especially during shortages.
Recent regulatory efforts aim to incentivize new entrants, improve supply stability, and regulate prices, but market consolidation and supply chain challenges persist.
Price projections suggest continued volatility in the short term, with potential stabilization and slight price declines if supply obstacles are addressed through regulatory and technical innovations.
Stakeholders should adopt proactive strategies, focusing on supply chain resilience, regulatory intelligence, and alternative therapies to navigate this dynamic market effectively.

FAQs

What factors have historically caused CYTOMEL shortages?
Manufacturing complexities, stringent quality requirements, and low profit margins have led to limited supplier participation, resulting in periodic shortages.
How do regulatory changes impact CYTOMEL's market prices?
Regulatory approvals of generic competitors can increase supply and reduce prices, while restrictions or delays may exacerbate shortages and inflate prices.
Are there effective alternatives to CYTOMEL for hypothyroidism?
Yes, levothyroxine (T4) is the standard treatment. Liothyronine (T3) like CYTOMEL is reserved for specific indications due to its narrow therapeutic window.
What is the outlook on CYTOMEL's pricing stability?
Short-term fluctuations are expected, but long-term stability depends on regulatory support, manufacturing capacity, and clinical demand shifts.
How might technological innovations affect future CYTOMEL prices?
Advances in manufacturing and formulation may enhance supply stability, exerting downward price pressure and broadening patient access.

References

[1] American Thyroid Association. (2020). Hypothyroidism. Retrieved from https://www.thyroid.org/hypothyroidism/
[2] FDA. (2018). FDA approves new drug for hypothyroidism.
[3] Jonklaas, J., et al. (2015). Guidelines for the treatment of hypothyroidism. Thyroid, 25(12), 1-28.

Drug Price Trends for CYTOMEL

Average Pharmacy Cost for CYTOMEL

Market Analysis and Price Projections for CYTOMEL (Liothyronine Sodium)